Arena Pharmaceuticals, Eisai Expand Marketing and Supply Agreement for BELVIQ

Arena Pharmaceuticals (NASDAQ: ARNA) and Eisai announced today the expansion of the BELVIQ® (lorcaserin HCl) marketing and supply agreement between Arena Pharmaceuticals, Inc.'s wholly owned subsidiary, Arena Pharmaceuticals GmbH, and Eisai Inc. along with its parent company Eisai Co., Ltd. The expanded agreement provides Eisai with exclusive commercialization rights for all countries worldwide, except for South Korea, Taiwan, Australia, Israel and New Zealand. This agreement amends and restates the previous agreement that granted Eisai rights to commercialize BELVIQ in most of North and South America. Eisai's commercialization rights are subject to applicable regulatory approval.    "This new agreement not only expands Eisai's territory for commercialization, but it also prioritizes our global development program for BELVIQ," said Jack Lief, Arena's President and Chief Executive Officer. "Expanding our collaboration with Eisai provides the potential to make BELVIQ available to physicians and patients worldwide for weight management and creates a powerful platform to investigate this novel compound for possible new indications by leveraging our combined drug development and regulatory expertise."Lonnel Coats, Eisai Inc.'s President and See full press release